TY - JOUR
T1 - 10-Formyl-5,10-dideaza-acyclic-5,6,7,8-tetrahydrofolic acid (10-Formyl-DDACTHF)
T2 - A potent cytotoxic agent acting by selective inhibition of human GAR Tfase and the de novo purine biosynthetic pathway
AU - Marsilje, Thomas H.
AU - Labroli, Marc A.
AU - Hedrick, Michael P.
AU - Jin, Qing
AU - Desharnais, Joel
AU - Baker, Stephen J.
AU - Gooljarsingh, Lata T.
AU - Ramcharan, Joseph
AU - Tavassoli, Ali
AU - Zhang, Yan
AU - Wilson, Ian A.
AU - Beardsley, G. Peter
AU - Benkovic, Stephen J.
AU - Boger, Dale L.
N1 - Funding Information:
We gratefully acknowledge the financial support of the National Institute of Heath (CA 63536) and The Skaggs Institute for Chemical Biology. We gratefully thank Dr. Gerrit Jansen (University Hospital Utrecht, The Netherlands) for kindly supplying the CCRF-CEM/MTX cell line for the cytotoxicity studies.
PY - 2002
Y1 - 2002
N2 - The synthesis of 10-formyl-DDACTHF (3) as a potential inhibitor of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) is reported. Aldehyde 3, the corresponding γ- and α-pentaglutamates 21 and 25 and related agents were evaluated for inhibition of folate-dependent enzymes including GAR Tfase and AICAR Tfase. The inhibitors were found to exhibit potent cytotoxic activity (CCRF-CEM IC50 for 3=60 nM) that exceeded their enzyme inhibition potency [Ki (3)=6 and 1 μM for Escherichia coli GAR and human AICAR Tfase, respectively]. Cytotoxicity rescue by medium purines, but not pyrimidines, indicated that the potent cytotoxic activity is derived from selective purine biosynthesis inhibition and rescue by AICAR monophosphate established that the activity is derived preferentially from GAR versus AICAR Tfase inhibition. The potent cytotoxic compounds including aldehyde 3 lost activity against CCRF-CEM cell lines deficient in the reduced folate carrier (CCRF-CEM/MTX) or folylpolyglutamate synthase (CCRF-CEM/FPGS-) establishing that their potent activity requires both reduced folate carrier transport and polyglutamation. Unexpectedly, the pentaglutamates displayed surprisingly similar Ki's versus E. coli GAR Tfase and only modestly enhanced Ki's versus human AICAR Tfase. On the surface this initially suggested that the potent cytotoxic activity of 3 and related compounds might be due simply to preferential intracellular accumulation of the inhibitors derived from effective transport and polyglutamation (i.e., ca. 100-fold higher intracellular concentrations). However, a subsequent examination of the inhibitors against recombinant human GAR Tfase revealed they and the corresponding γ-pentaglutamates were unexpectedly much more potent against the human versus E. coli enzyme (Ki for 3, 14 nM against rhGAR Tfase versus 6 μM against E. coli GAR Tfase) which also accounts for their exceptional cytotoxic potency.
AB - The synthesis of 10-formyl-DDACTHF (3) as a potential inhibitor of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) is reported. Aldehyde 3, the corresponding γ- and α-pentaglutamates 21 and 25 and related agents were evaluated for inhibition of folate-dependent enzymes including GAR Tfase and AICAR Tfase. The inhibitors were found to exhibit potent cytotoxic activity (CCRF-CEM IC50 for 3=60 nM) that exceeded their enzyme inhibition potency [Ki (3)=6 and 1 μM for Escherichia coli GAR and human AICAR Tfase, respectively]. Cytotoxicity rescue by medium purines, but not pyrimidines, indicated that the potent cytotoxic activity is derived from selective purine biosynthesis inhibition and rescue by AICAR monophosphate established that the activity is derived preferentially from GAR versus AICAR Tfase inhibition. The potent cytotoxic compounds including aldehyde 3 lost activity against CCRF-CEM cell lines deficient in the reduced folate carrier (CCRF-CEM/MTX) or folylpolyglutamate synthase (CCRF-CEM/FPGS-) establishing that their potent activity requires both reduced folate carrier transport and polyglutamation. Unexpectedly, the pentaglutamates displayed surprisingly similar Ki's versus E. coli GAR Tfase and only modestly enhanced Ki's versus human AICAR Tfase. On the surface this initially suggested that the potent cytotoxic activity of 3 and related compounds might be due simply to preferential intracellular accumulation of the inhibitors derived from effective transport and polyglutamation (i.e., ca. 100-fold higher intracellular concentrations). However, a subsequent examination of the inhibitors against recombinant human GAR Tfase revealed they and the corresponding γ-pentaglutamates were unexpectedly much more potent against the human versus E. coli enzyme (Ki for 3, 14 nM against rhGAR Tfase versus 6 μM against E. coli GAR Tfase) which also accounts for their exceptional cytotoxic potency.
UR - http://www.scopus.com/inward/record.url?scp=0036283633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036283633&partnerID=8YFLogxK
U2 - 10.1016/S0968-0896(02)00102-5
DO - 10.1016/S0968-0896(02)00102-5
M3 - Article
C2 - 12057663
AN - SCOPUS:0036283633
SN - 0968-0896
VL - 10
SP - 2739
EP - 2749
JO - Bioorganic and Medicinal Chemistry
JF - Bioorganic and Medicinal Chemistry
IS - 8
ER -